Sponsor activities

THURSDAY, 22 APRIL

10.50-11.20
IPP1 - ESCCA Industrial Partner Presentation:
Implementation of the new DxFLEX clinical flow cytometer in a Hematology laboratory
Dr Françoise Durrieu 

Programme in the Beckman Coulter room - Sponsor room 1:

THURSDAY, 22 APRIL

12.40-13.10
Meet the Expert parallel session I:
Towards a new standard in flow-cytometric MRD assessment in AML: Innovative consensus approach of the I-BFM-FLOW network
Barbara Buldini (Padua, IT) / Michael Dworzak (Vienna, AT)

12.40-13.10 Meet the Expert parallel session II:
CD169 AND CD64 expression in leukocytes as novel tool to discriminate viral versus bacterial infections: new opportunity for action
Claudia Matteucci (Rome, IT)

13.10-13.40
Meet the Expert session:
Workflow optimization in clinical high-throughput flow cytometry: handling of reagents and sample preparation, data acquisition and data interpretation applying artificial intelligence
Wolfgang Kern (Munich, DE)

FRIDAY, 23 APRIL

12.30-13.00
Meet the Expert parallel session:
T-cell responses to SARS-CoV-2 infection
Dan Payne (Leeds, UK)

13.00-13.30
Meet the Expert parallel session I:
Deciphering the transcriptome in hematopoiesis using the CytoFLEX platform
Jan-Henning Klusmann (Halle, DE)

13.00-13.30
Meet the Expert parallel session II:
Self-service sorting with the newest member of the CytoFLEX family
Karen Hogg (York, UK)

SATURDAY, 24 APRIL 2021

12.30-13.30
Meet the Expert session:
EU IVDR regulation: understanding the new requirements for a smooth transition
Maurizio Suppo (Geel, BE) / Brice Ezzouaouy (Marseille, FR)

FRIDAY, 23 APRIL

12.05-12.35 
IPP03 - ESCCA Scientific Industrial Parter Presentation:
State-of-the-art reporting for MRD assessment
María Rodríguez Martín – Product Specialist at Cytognos

Day-to-day programme in the Cytognos room - Sponsor room 3:

For the full details, please click here.

SATURDAY, 24 APRIL

12.05-12.35 
IPP5 - ESCCA Scientific Industrial Parter Presentation:
Implementing CyTOF® technology for standardized, high-dimensional assays for clinical research
From cell types to tissue: analyse >50 functional and phenotypic markers simultaneously on the Helios and Hyperion™ Imaging System
Dr. Glòria Martrus, Field Application Specialist, Fluidigm

Programme in the Fluidigm room - Sponsor room 6:

THURSDAY, 22 APRIL

13:00 – 13:50 CEST
Integrating mass cytometry into candidate vaccine development
Patrick Reeves, PhD, Instructor in Medicine, Harvard Medical School, Team Leader, Vaccine and Immunotherapy Center, Massachusetts General Hospital
Information: In this presentation, Patrick Reeves, PhD, discusses how mass cytometry can benefit vaccine research programs to overcome hurdles, deliver valuable insights and inform the evaluation of candidate vaccines.

13:00 – 13:50 CEST
Systems-Level Immunomonitoring in Human Subjects
Petter Brodin, MD, PhD, Associate Professor of Immunology, SciLifeLab, Department of Women's and Children's Health, Department of Newborn Medicine, Karolinska University Hospital, Karolinska Institutet
Information: In this seminar Dr. Petter Brodin presents his most recent data on the application of systems-level immune monitoring using mass cytometry in a variety of clinical studies. He discusses his lab’s innovative approaches to tackling the challenges of longitudinal sampling and analysis of whole blood samples for immune monitoring as well as the biologic results obtained from several studies.

13:00 – 13:50 CEST
The use of the Maxpar Direct Immune Profiling System in the COntAGIouS COVID-19 trial 
Frederik De Smet, MSc, PhD, Assistant Professor, University of Leuven, Belgium
Information: In this presentation, Frederik De Smet, MSc, PhD, presents early data from the COvid-19 Advanced Genetic and Immunologic Sampling (COntAGIouS) clinical research study (NCT04327570) using the Maxpar® Direct™ Immune Profiling Assay™ and Maxpar Pathsetter™ software.
The COntAGIouS trial is a collaboration led by the research university
KU Leuven and University Hospital Leuven to perform an in-depth characterization of the dynamic host immune response to coronavirus SARS-CoV-2.

SATURDAY, 24 APRIL

14.00-14.30 
IPP06 - ESCCA Scientific Industrial Parter Presentation:
Creating Efficiency in the Lab with Full Spectrum Cytometry
Alex Zhong, Cytek Biosciences; Key Account Marketing Manager

Learn how:

• Succeeding with validated conventional cytometry assays on full spectrum flow cytometers
• Expanding assays for use with full spectrum flow cytometers
• Generating data from bone marrow samples from healthy donors and donors with acute myeloid leukemia (AML)

Programme in the Fluidigm room - Sponsor room 6:

Information will follow

Programme in the Agilent room - Sponsor room 7:

THURSDAY, 22 APRIL

13.00-14.00 
Introduction to the NovoCyte Flow Cytometer Family & NovoExpress Software
Introduction to the NovoCyte Flow Cytometer Family with a demonstration of the easy-to-use NovoExpress Software for Acquisition and Analysis.
Speakers:
- Stephan Jansen, Business Manager D.A.CH, Agilent
- Steve Rackstraw, Business Manager UK.IE, Agilent

FRIDAY, 23 APRIL

12:35 – 13:30 
Introduction to the NovoCyte Flow Cytometer Family & NovoExpress Software
Introduction to the NovoCyte Flow Cytometer Family with a demonstration of the easy-to-use NovoExpress Software for Acquisition and Analysis.
Speakers:
- Stephan Jansen, Business Manager D.A.CH, Agilent
- Steve Rackstraw, Business Manager UK.IE, Agilent

Programme in the Immunostep room - Sponsor room 8:

THURSDAY, 22 APRIL

13:00 -13:30
An Immunocapture-based Assay For Detecting Extracelular Vesicles By Flow Cytometry 
Oscar Gala (International Department, Immunostep)

THURSDAY, 22 APRIL

12:35 -13:05
An Immunocapture-based Assay For Detecting Extracelular Vesicles By Flow Cytometry
Oscar Gala (International Department, Immunostep)

Programme in the IQ Products room - Sponsor room 9:

THURSDAY, 22 APRIL

13.00-14.00 
Flow cytometric analysis of Hemoglobin S and F in a Sickle Cell Disease gene therapy clinical trial
Speaker: Amanda McCabe, PhD (USA)
Expression of hemoglobin F and hemoglobin S is monitored in patients with sickle cell disease both pre and post gene therapy using flow cytometry.

FRIDAY, 23 APRIL

12.35-13.30 
Flow cytometric analysis of fetal red blood cells in the diagnosis of fetomaternal hemorrhage
Speaker: Carian Boorsma, PhD (NL)
Conventional assays for fetomaternal hemorrhage have low reproducibility, high CV values and a risk for false positive results. By using a two-marker flow cytometry method, the detection of fetal red blood cells in the mother blood can be perform on an accurate, precise and reproducible manner.

SATURDAY, 24 APRIL 

13.00-14.00
Heparin Induced Thrombocytopenia (HIT) and the diagnosis of HIT
Speaker: Chefarzt Dr. Garritsen (DE)
Heparin-induced thrombocytopenia (HIT) is an immune-mediated distinct syndrome in which laboratory detection of the pathogenic antibodies is diagnostically useful. The present functional flow cytometric assay, the HITAlert™ kit, determines the capacity of the patient’s serum to activate platelets in presence of heparin (similar in concept to the gold-standard, the radioactive serotonin-release assay).

Programme in the Miltenyi room - Sponsor room 10:

FRIDAY, 23 APRIL

12.45-13.25
Speaker: Dr. Michal Besser
On-site production of CAR T cells for therapy
- Comparison of CD19 CART T cell production for NHL and ALL patients
- Advantages of on-site CAR T production
- QC requirements for on-site CAR T production

Michal Besser, PhD is the head of laboratory at The Ella Lemelbaum Institute for Immuno-Oncology and the scientific director of the ABC GMP facility at the Sheba Medical Center in Israel. Dr. Besser is an Assistant Professor at the Department of Clinical Immunology and Microbiology at Tel Aviv University. She completed her undergraduate studies and PhD at the University of Munich, Germany and her postdoctoral research at the Weizmann Institute of Science, Israel. The Besser lab is specialized in the clinical production of CAR T cells and Tumor Infiltrating Lymphocytes (TIL) for therapy of cancer patients. Adoptive cell therapy serves as a platform for a wide range of research projects, which mainly seek the understanding and improvement of cellular therapies and immunotherapy.